Robot Mobility Systems Receives $75 Million in Series D Funding from Wandercraft

In a significant stride for the European robotics industry, Wandercraft, a pioneering company based in France, has secured a Series D round of funding totalling $75 million. This funding round, led by Renault Group, aims to propel Wandercraft into its next phase of growth, with a focus on bringing innovative robotics technology to market.

The funding will primarily be used to accelerate the commercial deployment of Eve, the world's first self-balancing personal exoskeleton, which is expected to hit the market as early as 2026. Eve is designed to enhance mobility for individuals, offering a promising solution for those with mobility impairments.

Renault Group, Wandercraft's first commercial partner and customer of the industrial-grade robot, Calvin-40, will also contribute its industrial expertise to scale up production of Wandercraft's exoskeletons and industrial robots. Calvin-40, named for its development time of just 40 days, is the first humanoid robot developed by a European company, intended for physically demanding tasks.

The funding will also facilitate the industrial development and rollout of Calvin-40 and the broader Calvin humanoid family. Calvin-40's rapid development was made possible by utilizing Wandercraft's rapid development process and an existing, leading-edge robotics platform integrated with NVIDIA Isaac technologies.

Matthieu Masselin, CEO and Co-founder of Wandercraft, expressed his delight at the recent achievements, including global expansion, pivotal clinical trials, and the readiness of commercializing Eve, the personal exoskeleton. He stated that this new funding, alongside Renault Group, will enable Wandercraft to accelerate the industrial deployment of its unique robotics technology.

Access to health and mobility for all is a strategic focus supported by the French State through the France 2030 plan. The funding secured by Wandercraft will continue the company's mission of transforming how people live, move, and work across rehabilitation, home environments, and factory floors.

Paul-Francois Fournier, Executive Director of Bpifrance Innovation, expressed delight at renewing support for Wandercraft, which has been supported by the State with Bpifrance since 2017. The new funding will also be used to expand clinical adoption of Wandercraft's flagship rehabilitation system, Atalante X, and to develop and deploy Calvin-40 and the broader Calvin humanoid family.

The funding was secured from a consortium of investors, including Renault Group, PSIM fund, Bpifrance, Teampact Ventures, Quadrant Management, LBO France, Mutuelles Impact, Cemag Invest, Martagon Capital, and AG2R LA MONDIALE. The exact spelling of the name of Calvin-40's first customer and partner represented by Renault Group is not found in the provided search results.

This funding marks a significant milestone for Wandercraft, as it continues to push the boundaries of robotics technology and make a positive impact on people's lives. With Renault Group's support and expertise, Wandercraft is poised to bring its innovative solutions to a wider audience in the coming years.